Gene ther­a­pies for the cats and dogs you love? Penn-part­nered Scout Bio just raised $20M to make it a re­al­i­ty

The gene ther­a­py rev­o­lu­tion that’s been sweep­ing through biotech isn’t just about hu­mans any­more. A Penn-part­nered biotech called Scout Bio has just picked up a $20 mil­lion round to step up its work on once-and-done ther­a­pies for com­mon pet ail­ments.

Co-found­ed by leg­endary gene ther­a­py pi­o­neer and Penn in­ves­ti­ga­tor James Wil­son, Scout is us­ing some fa­mil­iar AAV tech to go af­ter dis­eases like chron­ic kid­ney dis­ease, chron­ic pain and the in­flam­ma­to­ry skin con­di­tion atopic der­mati­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER